Takeda Pharmaceutical (TAK) Depreciation & Amortization (CF) (2018 - 2026)

Takeda Pharmaceutical's Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 15.99% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $4.8 billion, a 4.09% decrease from a year earlier, with the FY2026 full-year figure at $4.8 billion, down 4.16% from the prior year.
• Depreciation & Amortization (CF) eased to $1.0 billion in Q1 2026 per TAK's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.3 billion in Q1 2022 and bottomed at $1.0 billion in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $1.3 billion (2023), against an average of $1.2 billion.
• Across the five-year window, Depreciation & Amortization (CF) gained 4.11% in 2023 and retreated 15.99% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $1.3 billion in 2022, then grew by 1.08% to $1.3 billion in 2023, then fell by 2.83% to $1.2 billion in 2024, then rose by 0.73% to $1.2 billion in 2025, then retreated by 15.65% to $1.0 billion in 2026.
• Per Business Quant, the three latest TAK Depreciation & Amortization (CF) figures stand at $1.0 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025).